WuXi STA tapped as preferred partner for Beta Pharma

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Pinkypills)
(Image: Getty/Pinkypills)

Related tags: WuXi STA

WuXi STA becomes the preferred CDMO partner for Beta Pharma as the company launches a Phase II clinical trial in China and begins preclinical research for an additional target.

STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec, will use the Marketing Authorization Holder (MAH) scheme to advance Beta Pharma’s late phase and commercial targets.

The MAH scheme, first piloted in 2017​, enables drug license holders to use a third party manufacturer instead of building GMP manufacturing capabilities in-house, as was previously required in China.

Read: Chinese R&D sector takes ‘significant step’ as outsourcing demand increases

Headquartered in Princeton, NJ, Beta Pharma is a biotech company focusing on oncology drug discovery and development.

Under the terms of the collaboration, the contract development and manufacturing organization (CDMO) WuXi STA will become the preferred partner for Beta Pharma, which in February 2019 launched​ a Phase II clinical trial in China for the target BPI-7711.

According to the company, BPI-7711 is a third generation of EGFR TKI and aims to treat mutation positive non-small cell lung cancer.

Beta Pharma also is in the preclinical research phase with another target, BPI-1178, for the treatment of metastatic breast cancer. It expects to submit a clinical application in the first quarter of 2019.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars